natgillin/translations-raw huggingface dataset:
For ART-experienced paediatric patients HIV genotypic testing is recommended.
Za pedijatrijske bolesnike koji su prethodno liječeni ART-om, preporučuje se testiranje genotipa HIV-a.
The increased exposure to darunavir in HIV-1 infected patients compared to healthy subjects may be explained by the higher concentrations of α1acid glycoprotein (AAG) in HIV-1 infected patients, resulting in higher darunavir binding to plasma AAG and, therefore, higher plasma concentrations.
Povišena izloženost darunaviru u bolesnika inficiranih s HIV-1 u usporedbi sa zdravim ispitanicima može se objasniti višim koncentracijama α1-kiselog glikoproteina (AAG, od engl. α1-acid glycoprotein) u bolesnika inficiranih s HIV-1, što može rezultirati višim vezivanjem darunavira na AAG u plazmi i stoga višim koncentracijama u plazmi.
There are currently inadequate data to determine whether co-administration of tenofovir disoproxil and cobicistat is associated with a greater risk of renal adverse reactions compared with regimens that include tenofovir disoproxil without cobicistat.
Trenutno nema prikladnih podataka pomoću kojih bi se odlučilo je li istodobna primjena tenofovir dizoproksila i kobicistata povezana s povećanim rizikom za bubrežne nuspojave u usporedbi s režimima koji uključuju tenofovir dizoproksil bez kobicistata.
The table below shows the efficacy data of the 48 week and 96 week analyses from the ARTEMIS trial:
U tablici ispod prikazani su analizirani podaci djelotvornosti nakon 48 i 96 tjedana iz ispitivanja ARTEMIS:
Therefore, concomitant treatment with such medicinal products for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (applies to darunavir boosted with either ritonavir or cobicistat).
Stoga je istodobno liječenje s takvim lijekovima čije su povišene koncentracije u plazmi povezane s ozbiljnim i/ili po život opasnim događajima kontraindicirano (odnosi se na darunavir pojačan bilo ritonavirom ili bilo kobicistatom).
Darunavir Krka 600 mg tablets may be used to provide suitable dose regimens (see section 4.2): For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.
Darunavir Krka od 600 mg tablete mogu se primjenjivati da bi se osigurali prikladni režimi doziranja (vidjeti dio 4.2): - Za liječenje HIV-1 infekcije u odraslih bolesnika prethodno liječenih antiretrovirusnom terapijom (ART), uključujući bolesnike koji su prethodno bili liječeni u znatnoj mjeri.
Investigations common increased blood creatinine
Pretrage često povišen kreatinin u krvi
This guidance is based on the half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 24 hours.
Ova smjernica temeljena je na poluvijeku darunavira u prisutnosti ritonavira te preporučenom intervalu doziranja od približno 24 sata.
As darunavir and ritonavir are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis.
S obzirom da darunavir i ritonavir imaju visok afinitet vezanja na proteine plazme, nije vjerojatno da bi se značajno uklonili hemodijalizom ili peritonealnom dijalizom.
The weight-based dose regimen for darunavir and ritonavir is provided in the tables above.
Režim doziranja za darunavir i ritonavir na temelju tjelesne težine naveden je u tablicama iznad.
When administered without food, the relative bioavailability of darunavir in the presence of low dose ritonavir is 30% lower as compared to intake with food.
Kada se uzima bez hrane, relativna bioraspoloživost darunavira u prisutnosti niske doze ritonavira je 30% niža u usporedbi s uzimanjem s hranom.
Your doctor will determine whether Darunavir Krka tablets is right for the child.
Liječnik će odrediti jesu li za Vaše dijete prikladne tablete lijeka Darunavir Krka.
HERBAL PRODUCTS St John's wort (Hypericum perforatum)
BILJNI PRIPRAVCI Gospina trava (Hypericum perforatum)
The observed hepatocellular and thyroid tumours in rodents are considered to be of limited relevance to humans.
Smatra se da su opaženi hepatocelularni tumori i tumori štitnjače u glodavaca od ograničenog značaja za ljude.
Concomitant use with strong CYP3A inducers is contraindicated, since these may reduce the exposure to cobicistat and darunavir leading to loss of therapeutic effect.
Istodobna primjena snažnih induktora CYP3A je kontraindicirana, budući da to može sniziti izloženost kobicistatu i darunaviru i dovesti do gubitka terapijskog učinka.
Data on comparison with a 150 mg once daily reference dose is lacking.
Nedostaju podaci usporedbe s referentnom dozom od 150 mg jedanput na dan.
An OBR consisting of at least 2 NRTIs with or without enfuvirtide (ENF) was used in both trials.
U oba ispitivanja primijenjen je OOR koji se sastojao od najmanje 2 NRTI sa ili bez enfuvirtida (ENF).
During the Phase III clinical trial GS-US-216-130 with darunavir/cobicistat (N=313 treatment-naïve and treatment-experienced subjects), 66.5% of subjects experienced at least one adverse reaction.
Tijekom kliničkog ispitivanja faze III GS-US-216-130 s darunavirom/kobicistatom (N=313 ispitanika koji prethodno nisu liječeni i ispitanici koji su prethodno liječeni), u 66,5% ispitanika javila se barem jedna nuspojava.
Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil.
Pogledajte dio 4.4 ako se klirens kreatinina koristi za prilagodbu doze tenofovirdizoproksila.
Darunavir Krka is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection.
Darunavir Krka je antiretrovirusni lijek koji se koristi za liječenje infekcije uzrokovane virusom humane imunodeficijencije (HIV).
≥ 30 kg to < 40 kg
≥ 30 kg do < 40 kg
Take your other HIV medicines used in combination with Darunavir Krka and ritonavir as recommended by your doctor.
- Ostale lijekove protiv HIV-a koje primjenjujete istodobno s lijekom Darunavir Krka i ritonavirom, uzimajte prema preporuci Vašeg liječnika.
400/100 mg twice daily
400/100 mg dvaput na dan
Darunavir may therefore have different contraindications and recommendations for concomitant medications depending on whether the compound is boosted with ritonavir (see sections 4.3, 4.4 and
Stoga, darunavir može imati različite kontraindikacije i preporuke za istodobno primijenjene lijekove, ovisno o tome je li djelatna tvar pojačana ritonavirom (vidjeti dijelove 4.3, 4.4 i 4.5).
Thyroid follicular cell adenomas were noted in male rats.
Folikularni stanični adenom štitnjače zabilježen je u muških štakora.
Rosuvastatin 10 mg once daily rosuvastatin AUC ↑ 48% rosuvastatin Cmax ↑ 144%
Rosuvastatin 10 mg jedanput na dan rosuvastatin AUC ↑ 48% rosuvastatin Cmax ↑ 144%
Darunavir is primarily metabolised by CYP3A.
Darunavir se primarno metabolizira putem CYP3A.
Avanafil to treat erectile dysfunction
Za liječenje erektilne disfunkcije Avanafil
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahtjevi za podnošenje PSUR-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7.
Darunavir/ritonavir should not be used in children below 3 years of age because of safety concerns (see sections 4.4 and 5.3).
Darunavir/ritonavir se ne smije primjenjivati u djece uzrasta ispod 3 godine zbog sigurnosnih razloga (vidjeti dijelove 4.4 i 5.3).
In addition, patients on a stable dose of these antidepressants who start treatment with boosted darunavir should be monitored for antidepressant response.
Dodatno, bolesnike na stabilnoj dozi tih antidepresiva koji započnu liječenje s pojačanim darunavirom mora se pratiti na odgovor na antidepresive.
Fentanyl Oxycodone Tramadol
Fentanil Oksikodon Tramadol
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Lijek se izdaje na ograničeni recept (vidjeti Prilog I.: sažetak opisa svojstava lijeka, dio 4.2).
MedDRA system organ class Frequency category
Klasifikacija organskih sustava prema MedDRA-i Kategorija učestalosti
30 film-coated tablets 60 film-coated tablets 90 film-coated tablets 180 film-coated tablets
30 filmom obloženih tableta 60 filmom obloženih tableta 90 filmom obloženih tableta 180 filmom obloženih tableta
Ciclosporin, everolimus, tacrolimus, sirolimus (for dampening down your immune system) as the therapeutic effect or side effects of these medicines might be increased.
- ciklosporin, everolimus, takrolimus, sirolimus (za prigušivanje imunološkog sustava), s obzirom na mogućnost pojačanog terapijskog učinka ili nuspojava tih lijekova.
Titanium dioxide (E171)
poli(vinilni alkohol) makrogol titanijev dioksid (E171)
When the recommendation is the same for darunavir when co-administered with a low dose ritonavir or cobicistat, the term “boosted darunavir” is used.
Kada je preporuka ista za darunavir istodobno primijenjen s niskom dozom ritonavira ili kobicistatom, korišten je termin „pojačan darunavir“.
Both arms used an optimised background regimen (OBR) of ≥ 2 NRTIs.
U obje skupine primijenjen je optimizirani osnovni režim (OOR) od ≥ 2 NRTI.
This guidance is based on the 15 hour half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 12 hours.
Ova smjernica temeljena je na 15 satnom poluvijeku darunavira u prisutnosti ritonavira te preporučenom intervalu doziranja od približno 12 sati.
As limited information is available on the use of darunavir in patients aged 65 and over, caution should be exercised in the administration of darunavir in elderly patients, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy (see sections 4.2 and 5.2).
S obzirom da su dostupni ograničeni podaci o primjeni darunavira u bolesnika u dobi od 65 godina i više, nužan je oprez kod primjene darunavira u starijih bolesnika zbog povećane učestalosti smanjene funkcije jetre te istodobne bolesti ili druge terapije (vidjeti dijelove 4.2 i 5.2).
No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, darunavir should be used with caution in these patients.
Ne preporučuje se prilagodba doze u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre, međutim, darunavir se u tih bolesnika mora primjenjivati s oprezom.
The child must take Darunavir Krka with food.
- Dijete mora uzimati lijek Darunavir Krka s hranom.
Cmax, ng/ml AUC12h, ng.h/ml Cmin, ng/ml n=11 for AUC12h
Cmax, ng/ml AUC12h, ng.h/ml Cmin, ng/ml n=11 za AUC12h
Cobicistat 150 mg given with darunavir 800 mg once daily enhances darunavir pharmacokinetic parameters in a comparable way to ritonavir (see section 5.2).
Kobicistat od 150 mg koji je primijenjen s 800 mg darunavira jedanput na dan, poboljšava farmakokinetičke parametre darunavira sličnu ritonaviru (vidjeti dio 5.2).
Repeated administration of darunavir to rats caused hepatic microsomal enzyme induction and increased thyroid hormone elimination, which predispose rats, but not humans, to thyroid neoplasms.
Ponovljena primjena darunavira štakorima uzrokovala je indukciju mikrosomalnih enzima jetre te povećanu eliminaciju hormona štitnjače, što je u štakora predispozicija za razvoj neoplazmi štitnjače, ali ne i u ljudi.
Eye disorders uncommon conjunctival hyperaemia, dry eye rare visual disturbance
Poremećaj oka manje često konjunktivalna hiperemija, suho oko rijetko poremećaj vida
These can include, but are not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.
Oni mogu uključivati, ali nisu ograničeni na, teški osip ili osip praćen vrućicom, općom malaksalošću, umorom, tupim bolovima u mišićima i zglobovima, stvaranjem mjehurića, oralnim lezijama, konjunktivitisom, hepatitisom i/ili eozinofilijom.
The steady-state pharmacokinetic parameters of darunavir were comparable when boosted with ritonavir.
Farmakokinetički parametri darunavira u stanju dinamičke ravnoteže bili su usporedivi kada je pojačan ritonavirom.
These results were confirmed in the analysis of data at 96 weeks of treatment in the TITAN trial, with 60.4% of patients in the darunavir/ritonavir arm having HIV-1 RNA < 50 copies/ml at week 96 compared to 55.2% in the lopinavir/ritonavir arm [difference: 5.2%, 95% CI (-2.8; 13.1)].
Ti su rezultati potvrđeni analizom podataka u 96. tjednu liječenja u ispitivanju TITAN, sa 60,4% bolesnika u skupini liječenoj darunavirom/ritonavirom koji su imali HIV-1 RNK < 50 kopija/ml u 96. tjednu u usporedbi s 55,2% u skupini liječenoj lopinavirom/ritonavirom [razlika: 5,2%, 95% CI (-2,8;13,1)].
In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents.
Pri donošenju odluke o početku liječenja darunavirom primijenjenog istodobno s niskom dozom ritonavira, mora se pažljivo razmotriti dosadašnje liječenje pojedinog bolesnika i obrasce mutacija povezanih s različitim lijekovima.
Applicable to darunavir boosted with cobicistat, not when boosted with ritonavir: Darunavir boosted with cobicistat is more sensitive for CYP3A induction than darunavir boosted with ritonavir.
Primjenjivo na darunavir pojačan s kobicistatom, ne kada je pojačan ritonavirom: - Darunavir pojačan s kobicistatom osjetljiviji je na CYP3A indukciju, nego darunavir pojačan s ritonavirom.
Treatment with darunavir/cobicistat 800/150 mg once daily during the second and third trimester has been shown to result in low darunavir exposure, with a reduction of around 90% in Cmin levels (see section 5.2).
Liječenje darunavirom/kobicistatom 800/150 mg jedanput na dan tijekom drugog i trećeg tromjesečja rezultiralo je niskom izloženošću darunaviru, sa smanjenjem od otprilike 90% Cmin razina (vidjeti dio 5.2).
Pravastatin 40 mg single dose pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63%
Pravastatin 40 mg jednokratna doza pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63%
The most frequent adverse reactions reported in clinical trials and as spontaneous reports are diarrhoea, nausea, rash, headache and vomiting.
Najčešće nuspojave prijavljene u kliničkim ispitivanjima i spontano prijavljene su proljev, mučnina, osip, glavobolja i povraćanje.
The dosage of other medicines might need to be changed since either their own or Darunavir Krka's therapeutic effect or side effects may be influenced when combined.
Postoji mogućnost da će biti potrebno promijeniti doziranje drugih lijekova, s obzirom na mogućnost promjene terapijskog učinka ili nuspojava tih lijekova ili lijeka Darunavir Krka kada se primjenjuju u kombinaciji.
Darunavir Krka might increase sugar levels in the blood.
Darunavir Krka može povisiti razine šećera u krvi.
Therefore, darunavir tablets should be taken with ritonavir and with food.
Stoga se darunavir tablete moraju uzimati s ritonavirom te uz hranu.
These may include yellowing of your skin or whites of your eyes, dark (tea coloured) urine, pale coloured stools (bowel movements), nausea, vomiting, loss of appetite, or pain, aching, or pain and discomfort on your right side below your ribs.
Oni mogu uključiti žutu boju kože ili bjeloočnica, tamnu mokraću (boje čaja), blijede stolice (pokreti crijeva), mučninu, povraćanje, gubitak apetita ili bol, probadanje ili bol i nelagodu na desnoj strani u predjelu ispod rebara.
Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates of these transporters can result in increased plasma concentrations of these compounds (e.g. dabigatran etexilate, digoxin, statins and bosentan; see the Interaction table below).
Ritonavir inhibira transportere P-glikoprotein, OATP1B1 i OATP1B3 te istodobna primjena sa supstratima ovih transportera može rezultirati povećanjem koncentracije ovih lijekova u plazmi (npr. dabigatran eteksilat, digoksin, statini i bosentan; vidjeti tablicu interakcija ispod).
Caution should be used in pregnant women with concomitant medications which may further decrease darunavir exposure (see sections 4.5 and 5.2).
U trudnica je potreban oprez s konkomitantnom terapijom koja može dodatno sniziti izloženost darunaviru (vidjeti dijelove 4.5 i 5.2).
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
U nekih bolesnika s uznapredovalom HIV infekcijom i oportunističkom infekcijom u povijesti bolesti, ubrzo nakon početka liječenja protiv HIV-a mogu se pojaviti znakovi i simptomi upale zbog prijašnjih infekcija.
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme započinjanja kombinirane antiretrovirusne terapije (KART) može se pojaviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
It is not recommended to alter the dose of ritonavir.
Ne preporučuje se mijenjati dozu ritonavira.
The recommendations for darunavir boosted with ritonavir are adequate also for darunavir boosted with cobicistat with regard to substrates of CYP3A4, CYP2D6, P-glycoprotein, OATP1B1 and OATP1B3 (see contraindications and recommendations presented in the section above).
Preporuke za darunavir pojačan s ritonavirom vezano uz supstrate CYP3A4, CYP2D6, P glikoproteina, OATP1B1 i OATP1B3 primjenjive su također za darunavir pojačan s kobicistatom (vidjeti kontraindikacije i preporuke navedene u dijelu iznad).
Darunavir was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks.
Karcinogeni potencijal darunavira procjenjivao se tijekom 104 tjedna, peroralnom primjenom darunavira u miševa i štakora.
Darunavir and ritonavir are inhibitors of CYP3A, CYP2D6 and P-gp.
Darunavir i ritonavir su inhibitori CYP3A, CYP2D6 i P-gp-a.
Some clinical studies suggest raltegravir may cause a modest decrease in darunavir plasma concentrations.
Neka klinička ispitivanja pokazuju da raltegravir može uzrokovati umjereno smanjenje koncentracija darunavira u plazmi.
Dose adjustment for buprenorphine may not be necessary when coadministered with darunavir/ritonavir but a careful clinical monitoring for signs of opiate toxicity is recommended.
Prilagodba doze buprenorfina možda neće biti potrebna kada se primjenjuje istodobno s darunavirom/ritonavirom, ali se preporučuje pažljivo kliničko praćenje znakova opijatne toksičnosti.
Darunavir in combination with ritonavir has no or negligible influence on the ability to drive and use machines.
Darunavir u kombinaciji s ritonavirom ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Darunavir Krka is used to treat adults and children of 3 years of age and above, and at least 15 kilogram body weight who are infected by HIV and who have already used other antiretroviral medicines.
Darunavir Krka se koristi za liječenje odraslih i djece u dobi od 3 godine i starije, tjelesne težine najmanje 15 kilograma, koji su zaraženi HIV-om te su prethodno koristili druge antiretrovirusne lijekove.
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme početka liječenja kombiniranom antiretrovirusnom terapijom (KART) može nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
The child must take Darunavir Krka always together with ritonavir.
- Dijete uvijek mora uzimati lijek Darunavir Krka zajedno s ritonavirom.
Pharmacokinetics of total darunavir (mean ± SD)
Farmakokinetika ukupnog darunavira (srednja vrijednost ± SD)
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered with darunavir and low dose ritonavir.
Preporučuju se alternativne ili dodatne kontracepcijske mjere kada se kontraceptivi na bazi estrogena primjenjuju istodobno s darunavirom i niskom dozom ritonavira.
The combination of darunavir and artemether/lumefantrine can be used without dose adjustments; however, due to the increase in lumefantrine exposure, the combination should be used with caution.
Kombinacija darunavira i artemetera/lumefantrina može se primijeniti bez prilagodbe doze, međutim, zbog povećane izloženosti lumefantrinu, tu se kombinaciju mora primjenjivati s oprezom.
H2-RECEPTOR ANTAGONISTS Ranitidine
ANTAGONISTI H2 RECEPTORA Ranitidin
Monitor for fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary.
Potrebno pratiti kako bi se uočile nuspojave fesoterodina ili solifenacina, može biti potrebno smanjenje doze fesoterodina ili solifenacina.
Darunavir is extensively metabolised by the hepatic CYP system and almost exclusively by isozyme CYP3A4.
Darunavir se ekstenzivno metabolira u jetrenom CYP sustavu, gotovo isključivo izoenzimom CYP3A4.
Concomitant treatment with any of the following medicinal products given the expected decrease in plasma concentrations of darunavir, ritonavir and cobicistat and the potential for loss of therapeutic effect (see sections 4.4 and 4.5).
Istodobno liječenje s bilo kojim od slijedećih lijekova, radi očekivanog smanjenja koncentracija darunavira, ritonavira i kobicistata u plazmi i potencijalnog gubitka terapijskog učinka (vidjeti dijelove 4.4 i 4.5).
The combination of boosted darunavir and artemether/lumefantrine can be used without dose adjustments; however, due to the increase in lumefantrine exposure, the combination should be used with caution.
Kombinacija pojačanog darunavira i artemetera/lumefantrina može se primijeniti bez prilagodbe doze, međutim, zbog povećane izloženosti lumefantrinu, tu se kombinaciju mora primjenjivati s oprezom.
Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases, especially during the first several months of darunavir/ritonavir treatment.
Mora se razmotriti pojačano praćenje AST/ALT u bolesnika s podležećim kroničnim hepatitisom, cirozom ili u bolesnika koji su prije liječenja imali povišenja transaminaza, posebno tijekom prvih nekoliko mjeseci liječenja darunavirom/ritonavirom.
In a multiple dose study with darunavir co-administered with ritonavir (600/100 mg) twice daily, it was demonstrated that the total plasma concentrations of darunavir in subjects with mild (Child-Pugh Class A, n=8) and moderate (ChildPugh Class B, n=8) hepatic impairment were comparable with those in healthy subjects.
U ispitivanjima primjene višestrukih doza darunavira primijenjenog istodobno s ritonavirom (600/100 mg) dvaput na dan, pokazalo se da su ukupne koncentracije darunavira u plazmi u ispitanika s blagim (Child-Pugh stadij A, n=8) i umjerenim (Child-Pugh stadij B, n=8) oštećenjem funkcije jetre usporediva s onom u zdravih ispitanika.
For use in these patients, more suitable formulations containing darunavir should be checked for their availability.
Za primjenu u tih bolesnika mora se provjeriti dostupnost prikladnijih oblika koji sadrže darunavir.